Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1654 1658 1676
This examiner grants 43% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18043882 | IMPROVED HIGHLY POTENT SPECIFIC HUMAN KUNITZ INHIBITOR OF FIBRINOLYTIC ENZYME PLASMIN | Final Rejection | The Regents of the University of California |
| 17441922 | SUMO PEPTIDES FOR TREATING NEURODEGENERATIVE DISEASES | Final Rejection | The Chinese University of Hong Kong |
| 18016154 | PEPTIDE ADJUVANT FOR ITS THERAPEUTIC APPLICATIONS IN VIRAL AND TUMOUR VACCINE DEVELOPMENT AND CANCER IMMUNOTHERAPY AND AUTOIMMUNE DISEASE DIAGNOSIS AND TREATMENTS | Non-Final OA | National University of Singapore |
| 19052168 | POLYPEPTIDES AND USES THEREOF | Final Rejection | MEDIMMUNE LIMITED |
| 17928764 | DIAGNOSIS AND MONITORING USING EXTRADOMAIN-B FIBRONECTIN TARGETED PROBES | Non-Final OA | Case Western Reserve University |
| 19016974 | COMPOSITION AND METHODS FOR REGULATING CHONDROCYTE PROLIFERATION AND INCREASING OF CARTILAGE MATRIX PRODUCTION | Non-Final OA | Institut National de la Santé et de la Recherche Médicale (INSERM) |
| 18035329 | FORMULATIONS COMPRISING ACTRII POLYPEPTIDE VARIANTS | Non-Final OA | Acceleron Pharma Inc. |
| 17700055 | TRIPLE GLUCAGON/GLP-1/GIP RECEPTOR AGONIST | Non-Final OA | HANMI PHARM. CO., LTD |
| 18039992 | Pharmaceutical Composition of GLP-1/GLP-2 Dual Agonists | Non-Final OA | Zealand Pharma A/S |
| 18323210 | PAR4 DERIVED PEPTIDES, ANALOGS AND USES THEREOF | Non-Final OA | Hadasit Medical Research Services and Development Ltd. |
| 18308203 | MODULATION OF HYPOXIA ASSOCIATED WITH STROKE | Final Rejection | Omniox, Inc. |
| 18249934 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | Non-Final OA | The University of Western Australia |
| 17172387 | LARAZOTIDE COMPOSITIONS AND METHODS FOR TREATING CANCER | Non-Final OA | Institut Gustave Roussy |
| 18023202 | MEDICINE CONTAINING METHEMOGLOBIN ENDOPLASMIC RETICULUM AS ACTIVE INGREDIENT AND USE THEREOF | Non-Final OA | KIMIGAFUCHI GAKUEN |
| 17665231 | TREATING A CANCER WITH PEPTIDES INCLUDING MELLITIN AND SHORTENED FORMS THEREOF CONJUGATED TO A SPECIFIC d-FORM PEPTIDE | Final Rejection | Twinpig Biolab, Inc. |
| 17442660 | Improved Bone Implant Matrix Comprising Proline-Rich Peptide And Method Of Preparing The Same | Non-Final OA | Industrie Biomediche Insubri S.A. |
| 17420927 | NOVEL PEPTIDES AND USES THEREOF | Non-Final OA | CENNA BIOSCIENCES INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy